Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention
暂无分享,去创建一个
Elizabeth C Mormino | Wesley K Thompson | Michael C Donohue | Philip S. Insel | W. Thompson | P. Aisen | M. Donohue | E. Mormino | P. Insel | Philip S Insel | Paul S Aisen
[1] William J. Jagust,et al. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease , 2017, NeuroImage.
[2] C. Rowe,et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease , 2011, Annals of neurology.
[3] Olivier Salvado,et al. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. , 2012, Brain : a journal of neurology.
[4] Clifford R. Jack,et al. Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition , 2016, Alzheimer's & dementia.
[5] Andrei G. Vlassenko,et al. Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data , 2011, Annals of neurology.
[6] Susan M Resnick,et al. Longitudinal patterns of β-amyloid deposition in nondemented older adults. , 2011, Archives of neurology.
[7] James G. Bollinger,et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis , 2019, Neurology.
[8] Samuel Iddi,et al. Bayesian latent time joint mixed effect models for multicohort longitudinal data , 2017, Statistical methods in medical research.
[9] Rik Ossenkoppele,et al. Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease , 2019, Alzheimer's & Dementia.
[10] Daniel R. Schonhaut,et al. PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.
[11] Anders Wallin,et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. , 2005, Clinical chemistry.
[12] B. Romeira,et al. Supplementary Note 1: Modeling of Grating Coupler , 2022 .
[13] Elizabeth C Mormino,et al. Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant , 2012, NeuroImage.
[14] Hélène Jacqmin-Gadda,et al. Estimating long-term multivariate progression from short-term data , 2014, Alzheimer's & Dementia.
[15] Bradford C. Dickerson,et al. Tau PET imaging in aging and early Alzheimer's disease , 2015 .
[16] M. Mintun,et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline , 2012, Annals of neurology.
[17] K. Blennow,et al. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. , 2019, JAMA neurology.
[18] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[19] Brian A. Gordon,et al. Widespread distribution of tauopathy in preclinical Alzheimer's disease , 2018, Neurobiology of Aging.
[20] Hanna Cho,et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum , 2016, Annals of neurology.
[21] Henrik Zetterberg,et al. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity , 2017, Nature Communications.
[22] O. Hansson,et al. Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. , 2019, JAMA neurology.
[23] M. Mintun,et al. Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects , 2012, The Journal of Nuclear Medicine.
[24] W. Thompson,et al. Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative , 2018, Alzheimer's & dementia.
[25] C. Rowe,et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.
[26] Roy W Jones,et al. On the path to 2025: understanding the Alzheimer’s disease continuum , 2017, Alzheimer's Research & Therapy.